Medicare GLP-1 Bridge program Beginning July 1, 2026 through December 31, 2027, eligible Medicare beneficiaries can access the following FDA-approved GLP-1 medications for weight loss : Wegovy (injection or tablet), Foundayo (tablet), and Zepbound (KwikPen only) for $50/month *** through the Medicare GLP-1 Bridge program
Call your clinician if burping comes with severe abdominal pain, repeated vomiting, inability to keep fluids down, yellowing of the skin or eyes, fever, or bloating that keeps getting worse
Trials with metabolic endpoints do not routinely report these cancer risk factors or concentrate enrollment in these patient populations
10.1016/j.jpsychores.2006.07.017 281
A confirmed result means the platform has been reviewed and approved under LegitScript's standards